MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program

First HuCAL-based Antibody to Enter Clinical Trial in Second
Indication

MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that
its licensing partner, Centocor R&D Inc., has enrolled a patient in a
Phase 2 clinical trial with a HuCAL-derived fully human antibody. A
Phase 1 clinical trial using the same antibody in oncology patients
was initiated in 2007 and is ongoing. The new trial is in an
immunology indication. This achievement marks the first antibody,
developed with MorphoSys's core technology, to enter human clinical
trials in a second indication with partners. The initiation of the
Phase 2 trial and the IND in a new indication trigger clinical
milestone payments to MorphoSys.

"Today's news marks further significant progress within our partnered
therapeutic antibody business and underpins the variety of commercial
opportunities inherent in our pipeline," commented Dr. Simon Moroney,
Chief Executive Officer of MorphoSys AG. "Indication broadening is at
the heart of the commercial success of several antibody therapies
currently on the market. For MorphoSys, additional indications
represent further value for our partnered drug pipeline as it leads
to higher clinical milestones and royalty-based income."

For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj,
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com

About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered
trademarks of MorphoSys AG

This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2008. All rights reserved.